Search
Search Results
##search.searchResults.foundPlural##
-
Hsa-miR-5581-3p and hsa-miR-542-3p target the F8 gene in hemophilia A without F8 mutations F8 gene is regulated by miRNAs
1060PDF: 457HTML: 211 -
NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?
3139PDF: 1678HTML: 1070 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
1949PDF: 775HTML: 195 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1287HTML: 362PDF: 788 -
GROUP-BASED TRAJECTORY MODELING OF PLATELET IN PATIENTS WITH APLASTIC ANEMIA: A STUDY BASED ON THE MIMIC DATABASE
926PDF: 932Suppl. Files: 612HTML: 92 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1419PDF: 893HTML: 208 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1598PDF: 1121HTML: 227 -
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
4525PDF: 2720HTML: 2241 -
CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA
2513PDF: 1568HTML: 2333Table1: 172 -
OUTCOME OF ANTIFUNGAL COMBINATION THERAPY FOR INVASIVE MOLD INFECTIONS IN HEMATOLOGICAL PATIENTS IS INDEPENDENT OF THE CHOSEN COMBINATION
1018PDF: 524HTML: 1671Figures: 143Fifures Sanz: 156tables Sanz: 163Untitled: 157 -
ClinicaI Reversible Myelopathy in T-Cell Lymphoblastic Lymphoma Treated with Nelarabine and Radiotherapy: Report of a Case and Review of Literature of an Increasing Complication
2315PDF: 958HTML: 1627Fig 1: 165Tab I: 190Cover Letter: 180 -
Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and G-CSF
1674PDF: 543HTML: 258 -
COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS COVID-19 IN CHILDREN AND ADOLESCENT.
1982PDF: 900HTML: 278 -
CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS CAR-T and Follicular Lymphoma
2072PDF: 1738HTML: 118 -
CORD BLOOD PLATELET LYSATE: IN VITRO EVALUATION TO SUPPORT THE USE IN REGENERATIVE MEDICINE. Cord and adult blood platelet lysates
1882PDF: 1088HTML: 232 -
GASTROINTESTINAL MYELOID SARCOMA A CASE PRESENTATION AND CRITICAL REVIEW OF THE LITERATURE GASTROINTESTINAL MYELOID SARCOMA
1152PDF: 564HTML: 198 -
WHAT ARE FUNGAL INFECTIONS?
4014PDF: 2303HTML: 27544de Pauw: 205 -
T-LYMPHOCYTES EXPRESSION OF TOLL-LIKE RECEPTORS 2 AND 4 IN ACUTE MYELOID LEUKEMIA PATIENTS WITH INVASIVE FUNGAL INFECTIONS Toll-like receptors 2 and 4 in Acute Myeloid Leukemia Patients with Invasive Fungal Infections
1691PDF: 654HTML: 312 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7192PDF: 2359HTML: 1703Table 1.: 183Table 2.: 199Table 3.: 179Table 4.: 178 -
Bordetella Bronchiseptica in the Immunosuppressed Population – A Case Series and Review.
2358PDF: 1249HTML: 1714CoverLetter: 157 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2727PDF: 976HTML: 5495 -
Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure Memory Cell Population Of Natural Killer Cells in COVID-19 and Cytomegalovirus Exposure
1080PDF: 872HTML: 280 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
8840PDF: 5941HTML: 87449Fig.1b: 161Fig.1c: 164Fig.2a: 155Fig.2b: 154Fig.4: 168Fig.2c: 155Fig.3: 161Tab.1: 209Tab.2: 187Tab.3: 175Tab.4: 195Fig1a: 155 -
OLDER ADULTS WITH PH NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA: A MONOCENTRIC EXPERIENCE ON CONSECUTIVE PATIENTS AGED MORE THAN 55 YEARS Older Adults with Ph Negative Acute Lymphoblastic Leukemia
1233PDF: 530Suppl. Files: 324HTML: 128 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1153PDF: 922HTML: 188 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1115PDF: 1001HTML: 172







